Literature DB >> 19300878

Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data.

W M Van Der Flier1, P Scheltens.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19300878     DOI: 10.1007/s12603-009-0041-x

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


× No keyword cloud information.
  22 in total

1.  Hippocampal volume discriminates between normal cognition; questionable and mild dementia in the elderly.

Authors:  H Wolf; M Grunwald; F Kruggel; S G Riedel-Heller; S Angerhöfer; A Hojjatoleslami; A Hensel; T Arendt; H Gertz
Journal:  Neurobiol Aging       Date:  2001 Mar-Apr       Impact factor: 4.673

2.  CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.

Authors:  F H Bouwman; S N M Schoonenboom; W M van der Flier; E J van Elk; A Kok; F Barkhof; M A Blankenstein; Ph Scheltens
Journal:  Neurobiol Aging       Date:  2006-06-19       Impact factor: 4.673

3.  Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders.

Authors:  Femke H Bouwman; Wiesje M van der Flier; Niki S M Schoonenboom; Evert J van Elk; Astrid Kok; Philip Scheltens; Marinus A Blankenstein
Journal:  Clin Chem       Date:  2006-08       Impact factor: 8.327

4.  PET of brain amyloid and tau in mild cognitive impairment.

Authors:  Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

5.  Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease.

Authors:  Jonghan Shin; Sang-Yoon Lee; So-Hee Kim; Young-Bo Kim; Seong-Jin Cho
Journal:  Neuroimage       Date:  2008-07-23       Impact factor: 6.556

6.  Longitudinal stability of CSF biomarkers in Alzheimer's disease.

Authors:  Kaj Blennow; Henrik Zetterberg; Lennart Minthon; Lars Lannfelt; Stig Strid; Peter Annas; Hans Basun; Niels Andreasen
Journal:  Neurosci Lett       Date:  2007-04-06       Impact factor: 3.046

Review 7.  CSF markers for incipient Alzheimer's disease.

Authors:  Kaj Blennow; Harald Hampel
Journal:  Lancet Neurol       Date:  2003-10       Impact factor: 44.182

8.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Authors:  Oskar Hansson; Henrik Zetterberg; Peder Buchhave; Elisabet Londos; Kaj Blennow; Lennart Minthon
Journal:  Lancet Neurol       Date:  2006-03       Impact factor: 44.182

9.  Longitudinal changes of CSF biomarkers in memory clinic patients.

Authors:  F H Bouwman; W M van der Flier; N S M Schoonenboom; E J van Elk; A Kok; F Rijmen; M A Blankenstein; P Scheltens
Journal:  Neurology       Date:  2007-09-04       Impact factor: 9.910

10.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Authors:  Clifford R Jack; Val J Lowe; Matthew L Senjem; Stephen D Weigand; Bradley J Kemp; Maria M Shiung; David S Knopman; Bradley F Boeve; William E Klunk; Chester A Mathis; Ronald C Petersen
Journal:  Brain       Date:  2008-02-07       Impact factor: 13.501

View more
  3 in total

1.  Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease.

Authors:  M W Weiner
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

2.  Editorial: can we improve care for patients with dementia?

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

3.  Use of biomarkers in Alzheimer's trials.

Authors:  B Vellas
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.